Literature DB >> 26032292

Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.

Alexander Fuchs1, Mathew Leigh2, Bastian Kloefer3, Jennifer B Dressman4.   

Abstract

Biorelevant media are commonly used to simulate the physiological composition of human intestinal fluids (HIF) in in vitro solubility and dissolution investigations. In comparison with the surfactant solutions or blank buffers, these media are able to better reflect the physiological solubility and dissolution behavior of poorly soluble active pharmaceutical ingredients (APIs). The aim of this investigation was to review the composition of FaSSIF and FaSSIF-V2 according to recently summarized data about the physiological composition of fasted state human intestinal fluid and propose an updated version, FaSSIF-V3. Furthermore the surface tension was considered as a possible surrogate parameter to gauge the physiological correctness of new versions of biorelevant media. Various prototypes of FaSSIF-V3 were prepared with each of the following five bile salts: taurocholate (TC), glycocholate (GC), tauroursodeoxycholate (TUDC), taurochenodeoxycholate (TCDC) and glycochenodeoxycholate (GCDC) as well as replacing lecithin with its hydrolysis products, lysolecithin and sodium oleate. Two additional media consisting of a mixture of glycocholate (GC) and taurocholate (TG), with or without 0.2mM cholesterol, were also investigated. Solubilities of ten model compounds in various prototypes of FaSSIF-V3 were measured using HPLC-UV and compared to the solubilities in the existing biorelevant media (FaSSIF and FaSSIF-V2), fasted HIF, blank buffer and a 0.5% sodium dodecyl sulfate (SDS) solution. Additionally, the influence on the surface tension properties of various combinations of bile salts, phospholipids and their hydrolysis products and cholesterol in these media was investigated and an attempt was made to calculate the CMC of the various generations of FaSSIF. The results demonstrated that the amount and the type of phospholipids as well as the type of bile salt had a significant influence on the solubility and surface tension in the various FaSSIF-V3 prototypes and existing biorelevant media. In contrast to results with biorelevant media, it was demonstrated that blank buffers generally underestimate and SDS solutions highly overestimate the physiological relevant solubilities of all investigated APIs. The prototype containing FaSSIF-V3-GC/TC_Chol was able to better reflect the solubilities of the most investigated APIs in fasted HIF than the existing media, and it also matched the physiological surface tension reported for the fasted human gut, and was designated FaSSIF-V3.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile salts; Biorelevant media; FaSSIF; Fasted state; Human intestinal fluid; Lysolecithin; Solubility; Surface tension

Mesh:

Substances:

Year:  2015        PMID: 26032292     DOI: 10.1016/j.ejpb.2015.05.015

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  13 in total

1.  Crystallization from Supersaturated Solutions: Role of Lecithin and Composite Simulated Intestinal Fluid.

Authors:  Anura S Indulkar; Yi Gao; Shweta A Raina; Geoff G Z Zhang; Lynne S Taylor
Journal:  Pharm Res       Date:  2018-06-18       Impact factor: 4.200

2.  Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.

Authors:  Yufeng Zhang; Hua Liu; Minghui Johnson Tang; Nicolas James Ho; Tsun Lam Shek; Zhijun Yang; Zhong Zuo
Journal:  AAPS J       Date:  2021-03-04       Impact factor: 4.009

3.  Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.

Authors:  Chara Litou; Maria Vertzoni; Constantinos Goumas; Vassilis Vasdekis; Wei Xu; Filippos Kesisoglou; Christos Reppas
Journal:  Pharm Res       Date:  2016-03-14       Impact factor: 4.200

4.  Influence of Physiological Gastrointestinal Surfactant Ratio on the Equilibrium Solubility of BCS Class II Drugs Investigated Using a Four Component Mixture Design.

Authors:  Zhou Zhou; Claire Dunn; Ibrahim Khadra; Clive G Wilson; Gavin W Halbert
Journal:  Mol Pharm       Date:  2017-08-22       Impact factor: 4.939

Review 5.  Computational prediction of drug solubility in water-based systems: Qualitative and quantitative approaches used in the current drug discovery and development setting.

Authors:  Christel A S Bergström; Per Larsson
Journal:  Int J Pharm       Date:  2018-02-06       Impact factor: 5.875

6.  Characterization of Solubilizing Nanoaggregates Present in Different Versions of Simulated Intestinal Fluid.

Authors:  Andrew J Clulow; Albin Parrow; Adrian Hawley; Jamal Khan; Anna C Pham; Per Larsson; Christel A S Bergström; Ben J Boyd
Journal:  J Phys Chem B       Date:  2017-11-21       Impact factor: 2.991

7.  Topography of Simulated Intestinal Equilibrium Solubility.

Authors:  Claire Dunn; Jeremy Perrier; Ibrahim Khadra; Clive G Wilson; Gavin W Halbert
Journal:  Mol Pharm       Date:  2019-04-16       Impact factor: 4.939

8.  Selection of In Vivo Predictive Dissolution Media Using Drug Substance and Physiological Properties.

Authors:  Deanna M Mudie; Nasim Samiei; Derrick J Marshall; Gregory E Amidon; Christel A S Bergström
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

9.  Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models.

Authors:  Christian Wagner; Filippos Kesisoglou; Xavier J H Pepin; Neil Parrott; Arian Emami Riedmaier
Journal:  AAPS J       Date:  2021-06-17       Impact factor: 4.009

10.  Dual Level Statistical Investigation of Equilibrium Solubility in Simulated Fasted and Fed Intestinal Fluid.

Authors:  Bayan E Ainousah; Jeremy Perrier; Claire Dunn; Ibrahim Khadra; Clive G Wilson; Gavin Halbert
Journal:  Mol Pharm       Date:  2017-11-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.